Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAD51 | Q06609 | 2/20 | 0.57 |
| ▸ | DHODH | Q02127 | 1/20 | 0.45 |
| ▸ | GHSR | Q92847 | 1/20 | 0.44 |
| ▸ | IDH1 | O75874 | 1/20 | 0.41 |
| ▸ | MMP12 | P39900 | 1/20 | 0.40 |
| ▸ | MMP13 | P45452 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | MMP8 | P22894 | 1/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.39 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.39 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.38 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.38 |
| ▸ | CASR | P41180 | 1/20 | 0.37 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14359001 | 0.85 | ENPP2 (0.46) | RAD51DHODHGHSRIDH1MMP12 | |
| SCHEMBL14361823 | 0.83 | RAD51 (0.62) | RAD51MMP13MMP2MMP8KMT2A | |
| SCHEMBL14358614 | 0.83 | RAD51 (0.56) | RAD51GHSRMMP2SIRT1PRMT1 | |
| SCHEMBL14358542 | 0.81 | RAD51 (0.60) | RAD51MEN1KMT2A | |
| SCHEMBL11592877 | 0.78 | DHODH (0.56) | DHODHGHSRMMP2MMP8MTNR1B | |
| SCHEMBL14358661 | 0.77 | RAD51 (0.59) | RAD51KMT2A | |
| SCHEMBL15116962 | 0.77 | KDM4E (0.44) | DHODHMTNR1BKMT2ACASR | |
| SCHEMBL11596285 | 0.75 | CA12 (0.52) | DHODHCASR | |
| SCHEMBL19210838 | 0.74 | RAD51 (0.53) | RAD51GHSRKMT2A | |
| SCHEMBL14358809 | 0.74 | RAD51 (0.51) | RAD51 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2724156-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER AND AUTOIMMUNE DISEASE | The Jackson Laboratory (US) | 2014-04-30 | — | — | EP | claimed |
| US-20130184342-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER AND AUTOIMMUNE DISEASE | THE JACKSON LABORATORY (US) | 2013-07-18 | — | — | US | claimed |
| WO-2013003112-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER AND AUTOIMMUNE DISEASE | THE JACKSON LABORATORY (US) | 2013-01-03 | — | — | WO | claimed |
| US-10207988-B2 | Methods and compositions for treatment of cancer and autoimmune disease | THE JACKSON LABORATORY (US) | 2019-02-19 | — | — | US | disclosed |
| EP-2724156-B1 | METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER AND AUTOIMMUNE DISEASE | JACKSON LAB (US) | 2017-08-16 | — | — | EP | disclosed |
| EP-2724156-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER AND AUTOIMMUNE DISEASE | The Jackson Laboratory (US) | 2014-04-30 | — | — | EP | disclosed |
| US-20130184342-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER AND AUTOIMMUNE DISEASE | THE JACKSON LABORATORY (US) | 2013-07-18 | — | — | US | disclosed |
| WO-2013003112-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER AND AUTOIMMUNE DISEASE | THE JACKSON LABORATORY (US) | 2013-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130184342-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER AND AUTOIMMUNE DISEASE | BAK1, SSB, MRE11 | RAD51 36/4885DHODH 887/4885GHSR 4493/4885 |
| US-10207988-B2 | Methods and compositions for treatment of cancer and autoimmune disease | BAK1, SSB, MRE11 | RAD51 36/4885DHODH 887/4885GHSR 4493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.